February 26, 2010, European Patent Office (EPO) has notified its decision to grant DNA Therapeutics' first European patent of Dbait. This approval greatly strengthens the company's IP assets, and further secures the development of its lead product.
January 12, 2010, US Patent and Trademark Office (USPTO) has notified its decision to grant DNA Therapeutics' second Dbait patent.
2009
October 23, 2009, Dr. Marie Dutreix, co-inventor of siDNA technology and co-founder of DNA Therapeutics, received an award of the Antony Bernard Foundation against Cancer in union with the General Council of the Department Oise, the Municipality of Beauvais and the Committee of the Oise League against Cancer.
July 21, 2009, the article entitled "Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response" was published in PLoS ONE, 4:e6298. This paper describes the molecular and cellular mechanisme of action of Dbait molecules.
July 17, 2009, French innovation promotion agency "Oséo" provided a €550 000 loan to DNA Therapeutics for the CMC (Chemistry-Manufacturing-Control) development, part of the regulatory preclinical development program of Dbait.
April 27, 2009, The French Business Angels in Health awarded the Prize of Innovative Enterpreneur in Health 2008 to the co-founder, Chairman & CEO of DNA Therapeutics, Prof. Jian-Sheng SUN.
February 15, 2009, the article entitled "Small-molecular drugs mimicking DNA damage (Dbait): a new strategy for sensitizing tumors to radiotherapy" was published in Clinical Cancer Research, 15:1308. This paper describes the Dbait molecules, their mechanisms of action and proofs of concept in several human radio-resistant tumors xenografted on nude mice.
January 29, 2009, successful closing of DNA Therapeutics' Series A equity investment round. The investor syndicate led by SGAM SEFTI with two of the previous seed investors, Blue Medical Investments and G1J-Ile de France, is committed to invest 2.2 million EUR based on certain milestones to be met. Since June 2008, DNA Therapeutics has raised 3 million EUR (US$4 million) through this Series A and the previous seed round led by Inserm-Transfert Initiative, with BMI, G1J and a group of international business angels. Clic for PDF of the Press Release.
January 13, 2009, US Patent and Trademark Office (USPTO) issued DNA Therapeutics' core siDNA patent. This first approval among the company's IP portfolio greatly strengthens its assets, and secures the development of its lead product Dbait.
2008
September 12, 2008, US Patent and Trademark Office (USPTO) has notified its decision to grant DNA Therapeutics' core siDNA patent. This first approval among the company's IP portfolio greatly strengthens its assets, and secures the development of its lead product Dbait.
September 8, 2008, Inserm Transfer Initiative and G1J-Ile de France announced the execution of the seed financing of DNA Therapeutics specialized in developing innovative medicines in oncology. The syndicate of investors, led by Inserm Transfer Initiative, brings together G1J-Ile de France, Blue Medical Investment Group and International Business Angels, and invests 800k€. Clic for PDF of the Press Release. Following up the seed investment, Bernard Davitian was named vice chairman, Louis Jammayrac, Frédéric Zampatti and Anne-Catherine Jouanneau were named directors. Jian-Sheng Sun continues to serve as Chairman & CEO.
September 1, 2008, DNA Therapeutics has opened its office at 1311 Hua Neng Union Tower, 958 Lujiazuihuan Road, Pudong, 200120 Shanghai. This initiates DNA Therapeutics' strategic presence in this most vibrant and fast moving city and country in the world.
July 15, 2008, a six private-academic partner consortium led by DNA Therapeutics has been selected by the BiotecS 2008 program of the French National Agency for Research (ANR). It is eligible to €1.3 million (US$1.9 million) funding to a 3 year R&D reserach project aimed at developing new therapeutic strategy in glioblastoma combining DNA repair inhibitor (Dbait) and stereotactic irradiation ("GlioTherap").
2007
December 10, 2007, DNA Therapeutics has been assigned SME status by the European Medicines Agency (EMEA) and is now eligible to benefit from the provisions for administrative and financial assistance laid down in Regulation (EC) No 2049/2005.
July 13, 2007, DNA Therapeutics announced that Dr. François Thomas, MD, MBA, has been appointed to the board of directors. Dr. Thomas currently heads the Healthcare Practice at Bryan, Garnier & Co. Prior thereto, he was a life science partner at Atlas Venture, held various positions in pharmaceutical companies, and practiced medical oncology at the Institut Gustave Roussy.
DNA Therapeutics reports a novel mechanism of action and a biomarker of its lead molecule Dbait that open an innovative pathway-targeting in molecular cancer therapy. April 12th, 2007. Clic for PDF of the Press Release, or check for the Biospace site: http://www.biospace.com/news_story.aspx?StoryID=52038&full=1
DNA Therapeutics was granted the status of "Jeune Entreprise Innovante” (Young Innovative Company status) by the French Ministry of research & Technology and the French “IRS” which gives a 7 years tax saving benefit, on February 26th, 2007.
2006
DNA Therapeutics announces highly significant efficacy against xenografted tumors in animals thanks to its molecule Dbait, in association with standard radiotherapy. November 7th, 2006. Clic for PDF of the Press Release, or check for the Biospace site: http://www.biospace.com/news_story.aspx?StoryID=36244&full=1
DNA Therapeutics won the trophy of Life Scientice at the "concours Tremplin Entreprises" organized by French Senate French Senate, July, 2006 http://www.senat.fr/presse/cp20060706.html
top of page
home .
contact .
terms of use .
sitemap .
